OQRO

Weekly recap

Insider trades and Congress trades, week of Mar 2–8, 2026

In the week of Mar 2–8, 2026, insiders filed 212 open-market purchases worth about $129M and 1,507 open-market sales; the largest purchase was $10M of Larimar Therapeutics (LRMR) by James E Flynn; members of Congress disclosed 23 purchases and 42 sales; 10 purchases stood out against the company's record since 2006.

By filing date, Monday to Sunday. Every line links to its SEC, House or Senate record. Public filings, not investment advice.

Purchases that stand out against 20 years of filings

Measured against every open-market trade the company's insiders filed since 2006. See all of them on the rare insider trades page.

Largest insider purchases

Largest insider sales

Congress trades disclosed

Members report a value range, not an exact amount; the trade can be up to 45 days older than its report.

Executives who announced they are leaving

  • Turtle Beach (TBCH) · Mar 6, 2026

    “On March 5, 2026, Terry Jimenez, a director of Turtle Beach Corporation (the “Company”), notified the Company of his decision to resign as a director, effective as of March 6, 2026.” 8-K

  • Ashford Hospitality Trust (AHT) · Mar 6, 2026

    “On March 5, 2026, Ashford Hospitality Advisors, LLC (“Ashford Advisors”), a subsidiary of Ashford Inc. (the “Advisor”), agreed with Deric Eubanks, the Chief Financial Officer of Ashford Advisors and the Advisor, that, effective March 31, 2026 (the “Termination Date”), Mr. Eubanks would terminate employment with the Advisor, Ashford Advisors and their affiliates.” 8-K

  • Pacific Biosciences Of California (PACB) · Mar 6, 2026

    “On March 2, 2026, Michele Farmer notified Pacific Biosciences of California, Inc. (the "Company") that she is voluntarily resigning as Chief Accounting Officer of the Company effective on March 21, 2026, to pursue another opportunity.” 8-K

  • Bioaffinity Technologies (BIAF) · Mar 6, 2026

    “On March 5, 2026, Robert Anderson and Roby Joyce informed the Board of Directors (the “Board”) of bioAffinity Technologies, Inc., a Delaware corporation (the “Company”), of their decisions not to stand for re-election to the Board upon expiration of their current terms, which expire at the Company’s 2026 Annual Meeting of Stockholders, currently scheduled for April 30, 2026 (the “Annual Meeting”).” 8-K

  • Trump Media & Technology Group (DJT) · Mar 6, 2026

    “Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers. Robert Lighthizer notified Trump Media & Technology Group Corp. (the “Company”) of his resignation from its Board of Directors (the “Board”) and the committees on which he served, effective March 6, 2026.” 8-K

  • Braemar Hotels & Resorts (BHR) · Mar 6, 2026

    “On March 5, 2026, Ashford Hospitality Advisors, LLC (“Ashford Advisors”), a subsidiary of Ashford Inc. (the “Advisor”), agreed with Deric Eubanks, the Chief Financial Officer of Ashford Advisors and the Advisor, that, effective March 31, 2026 (the “Termination Date”), Mr. Eubanks would terminate employment with the Advisor, Ashford Advisors and their affiliates.” 8-K

  • Ckx Lands (CKX) · Mar 6, 2026

    “On March 5, 2026, each of Keith Duplechin and Daniel J. Englander notified CKX Lands, Inc. (the “Registrant”) that he would retire from his position as a member of the Registrant’s board of directors and thus will not stand for re-election at the Registrant’s 2026 annual meeting of stockholders.” 8-K

  • Midland States Bancorp (MSBI) · Mar 6, 2026

    “On March 5, 2026, Eric Lemke was terminated from his position as Chief Financial Officer of Midland States Bancorp, Inc. (the “Company”) and its wholly owned subsidiary, Midland States Bank (the “Bank”), and no longer serves as the Company’s principal financial officer or principal accounting officer.” 8-K

The company's own words, from the opening sentence of its Form 8-K (Item 5.02).

5% stakes filed (Schedules 13D and 13G)

Largest federal contract awards

See the record behind any of these

Each company page opens free with one real filing and the counts of the last 12 months. OQRO Pro adds the full history of every insider and company since 2006, the screener, alerts, Congress trades and fund moves.

Get OQRO ProOpen Larimar Therapeutics free$9.99 a month, cancel anytime